{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:17:57Z","timestamp":1787030277738,"version":"build-2736575974"},"reference-count":46,"publisher":"China Science Publishing & Media Ltd.","content-domain":{"domain":["engine.scichina.com"],"crossmark-restriction":false},"short-container-title":["ABBS"],"published-print":{"date-parts":[[2022,8,1]]},"DOI":"10.3724\/abbs.2022109","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T21:33:53Z","timestamp":1660167233000},"update-policy":"https:\/\/doi.org\/10.1360\/scp-crossmark-policy-page","source":"Crossref","is-referenced-by-count":12,"title":["Inhibition of the PIN1-NRF2\/GPX4 axis imparts sensitivity to cisplatin in cervical cancer cells"],"prefix":"10.3724","author":[{"given":"Zheng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiangsheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libing","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2026","published-online":{"date-parts":[[2022,8,17]]},"reference":[{"key":"CITATION1","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/S2214-109X(19)30482-6","volume":"8","author":"Arbyn M","year":"2020","unstructured":"Arbyn M, Weiderpass E, Bruni L, de Sanjos\u00e9 S, Saraiya M, Ferlay J, Bray F. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health, 2020, 8: e191-e203.","journal-title":"Lancet Glob Health"},{"key":"CITATION2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71: 209-249.","journal-title":"CA Cancer J Clin"},{"key":"CITATION3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(97)02250-2","volume":"350","author":"Landoni F","year":"1997","unstructured":"Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, Favini G. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet, 1997, 350: 535-540.","journal-title":"Lancet"},{"key":"CITATION4","doi-asserted-by":"publisher","first-page":"e240","DOI":"10.1016\/S1470-2045(16)30032-8","volume":"17","author":"Bentivegna E","year":"2016","unstructured":"Bentivegna E, Gouy S, Maulard A, Chargari C, Leary A, Morice P. Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review. Lancet Oncol, 2016, 17: e240-e253.","journal-title":"Lancet Oncol"},{"key":"CITATION5","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1200\/JCO.2014.58.4391","volume":"33","author":"Kitagawa R","year":"2015","unstructured":"Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T, Nishimura S. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: The Open-Label Randomized Phase III Trial JCOG0505. J Clin Oncol, 2015, 33: 2129-2135.","journal-title":"J Clin Oncol"},{"key":"CITATION6","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.2147\/DDDT.S106412","volume":"10","author":"Zhu H","year":"2016","unstructured":"Zhu H, Luo H, Zhang W, Shen Z, Hu X, Zhu X. Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Des Devel Ther, 2016, 10: 1885-1895.","journal-title":"Drug Des Devel Ther"},{"key":"CITATION7","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"Dasari S","year":"2014","unstructured":"Dasari S, Bernard Tchounwou P. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol, 2014, 740: 364-378.","journal-title":"Eur J Pharmacol"},{"key":"CITATION8","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/onc.2011.384","volume":"31","author":"Galluzzi L","year":"2012","unstructured":"Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M. Molecular mechanisms of cisplatin resistance. Oncogene, 2012, 31: 1869-1883.","journal-title":"Oncogene"},{"key":"CITATION9","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"Dixon SJ","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell, 2012, 149: 1060-1072.","journal-title":"Cell"},{"key":"CITATION10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3389\/fphys.2019.00139","volume":"10","author":"Lei P","year":"2019","unstructured":"Lei P, Bai T, Sun Y. Mechanisms of ferroptosis and relations with regulated cell death: a review. Front Physiol, 2019, 10:","journal-title":"Front Physiol"},{"key":"CITATION11","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.tcb.2020.02.009","volume":"30","author":"Stockwell BR","year":"2020","unstructured":"Stockwell BR, Jiang X, Gu W. Emerging mechanisms and disease relevance of ferroptosis. Trends Cell Biol, 2020, 30: 478-490.","journal-title":"Trends Cell Biol"},{"key":"CITATION12","doi-asserted-by":"publisher","first-page":"8765","DOI":"10.3390\/ijms21228765","volume":"21","author":"Reichert CO","year":"2020","unstructured":"Reichert CO, de Freitas FA, Sampaio-Silva J, Rokita-Rosa L, Barros PL, Levy D, Bydlowski SP. Ferroptosis mechanisms involved in neurodegenerative diseases. Int J Mol Sci, 2020, 21:","journal-title":"Int J Mol Sci"},{"key":"CITATION13","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1002\/jcp.29232","volume":"235","author":"Zhang X","year":"2020","unstructured":"Zhang X, Sui S, Wang L, Li H, Zhang L, Xu S, Zheng X. Inhibition of tumor propellant glutathione peroxidase 4 induces ferroptosis in cancer cells and enhances anticancer effect of cisplatin. J Cell Physiol, 2020, 235: 3425-3437.","journal-title":"J Cell Physiol"},{"key":"CITATION14","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s41598-018-19213-4","volume":"8","author":"Sato M","year":"2018","unstructured":"Sato M, Kusumi R, Hamashima S, Kobayashi S, Sasaki S, Komiyama Y, Izumikawa T. The ferroptosis inducer erastin irreversibly inhibits system xc\u2212 and synergizes with cisplatin to increase cisplatin\u2019s cytotoxicity in cancer cells. Sci Rep, 2018, 8:","journal-title":"Sci Rep"},{"key":"CITATION15","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/380544a0","volume":"380","author":"Ping Lu K","year":"1996","unstructured":"Ping Lu K, Hanes SD, Hunter T. A human peptidyl\u2013prolyl isomerase essential for regulation of mitosis. Nature, 1996, 380: 544-547.","journal-title":"Nature"},{"key":"CITATION16","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/cr.2014.109","volume":"24","author":"Lu Z","year":"2014","unstructured":"Lu Z, Hunter T. Prolyl isomerase PIN1 in cancer. Cell Res, 2014, 24: 1033-1049.","journal-title":"Cell Res"},{"key":"CITATION17","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1358\/dnp.2009.22.7.1414594","volume":"22","author":"Xu GG","year":"2009","unstructured":"Xu GG, Etzkorn FA. PIN1 as an anticancer drug target. Drug News Perspect, 2009, 22: 399-407.","journal-title":"Drug News Perspect"},{"key":"CITATION18","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/nature01116","volume":"419","author":"Zheng H","year":"2002","unstructured":"Zheng H, You H, Zhou XZ, Murray SA, Uchida T, Wulf G, Gu L. The prolyl isomerase PIN1 is a regulator of p53 in genotoxic response. Nature, 2002, 419: 849-853.","journal-title":"Nature"},{"key":"CITATION19","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrc.2016.49","volume":"16","author":"Zhou XZ","year":"2016","unstructured":"Zhou XZ, Lu KP. The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target. Nat Rev Cancer, 2016, 16: 463-478.","journal-title":"Nat Rev Cancer"},{"key":"CITATION20","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nrc2107","volume":"7","author":"Yeh ES","year":"2007","unstructured":"Yeh ES, Means AR. PIN1, the cell cycle and cancer. Nat Rev Cancer, 2007, 7: 381-388.","journal-title":"Nat Rev Cancer"},{"key":"CITATION21","doi-asserted-by":"crossref","unstructured":"Li H, Wang S, Zhu T, Zhou J, Xu Q, Lu Y, Ma D. PIN1 contributes to cervical tumorigenesis by regulating cyclin D1 expression. Oncol Rep 2006, 16: 491\u2013496.","DOI":"10.3892\/or.16.3.491"},{"key":"CITATION22","unstructured":"Ma JQ, Yang Y, Juan J, Guo CF, Tuerxun M, Ting W, Hasim A. Over-expression of prolyl isomerase PIN1 promotes cervical tumorigenesis and metastasis. Int J Clin Exp Pathol 2018, 11: 664\u2013674."},{"key":"CITATION23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.14336\/AD.2019.0415","volume":"11","author":"Guo YT","year":"2020","unstructured":"Guo YT, Lu Y, Jia YY, Qu HN, Qi D, Wang XQ, Song PY. Predictive value of PIN1 in cervical low-grade squamous intraepithelial lesions and inhibition of PIN1 exerts potent anticancer activity against human cervical cancer. Aging Dis, 2020, 11: 44-59.","journal-title":"Aging Dis"},{"key":"CITATION24","doi-asserted-by":"publisher","first-page":"6670","DOI":"10.18632\/oncotarget.3118","volume":"6","author":"Wang Z","year":"2015","unstructured":"Wang Z, Liu Y, Lu L, Yang L, Yin S, Wang Y, Qi Z. Fibrillin-1, induced by Aurora-A but inhibited by BRCA2, promotes ovarian cancer metastasis. Oncotarget, 2015, 6: 6670-6683.","journal-title":"Oncotarget"},{"key":"CITATION25","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12816","volume":"53","author":"Sun Q","year":"2020","unstructured":"Sun Q, Fan G, Zhuo Q, Dai W, Ye Z, Ji S, Xu W. Pin1 promotes pancreatic cancer progression and metastasis by activation of NF\u2010\u03baB\u2010IL\u201018 feedback loop. Cell Prolif, 2020, 53:","journal-title":"Cell Prolif"},{"key":"CITATION26","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.canlet.2019.03.024","volume":"452","author":"Hu Q","year":"2019","unstructured":"Hu Q, Qin Y, Ji S, Xu W, Liu W, Sun Q, Zhang Z. UHRF1 promotes aerobic glycolysis and proliferation via suppression of SIRT4 in pancreatic cancer. Cancer Lett, 2019, 452: 226-236.","journal-title":"Cancer Lett"},{"key":"CITATION27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nchembio.2239","volume":"13","author":"Doll S","year":"2017","unstructured":"Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, Irmler M. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol, 2017, 13: 91-98.","journal-title":"Nat Chem Biol"},{"key":"CITATION28","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/cdd.2015.158","volume":"23","author":"Xie Y","year":"2016","unstructured":"Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X, Kang R. Ferroptosis: process and function. Cell Death Differ, 2016, 23: 369-379.","journal-title":"Cell Death Differ"},{"key":"CITATION29","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","volume":"156","author":"Yang WS","year":"2014","unstructured":"Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah JH. Regulation of ferroptotic cancer cell death by GPX4. Cell, 2014, 156: 317-331.","journal-title":"Cell"},{"key":"CITATION30","doi-asserted-by":"publisher","first-page":"101107","DOI":"10.1016\/j.redox.2019.101107","volume":"23","author":"Dodson M","year":"2019","unstructured":"Dodson M, Castro-Portuguez R, Zhang DD. NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis. Redox Biol, 2019, 23:","journal-title":"Redox Biol"},{"key":"CITATION31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1158\/0008-5472.CAN-18-1968","volume":"79","author":"Liang C","year":"2019","unstructured":"Liang C, Shi S, Liu M, Qin Y, Meng Q, Hua J, Ji S. PIN1 maintains redox balance via the c-Myc\/NRF2 axis to counteract Kras-induced mitochondrial respiratory injury in pancreatic cancer cells. Cancer Res, 2019, 79: 133-145.","journal-title":"Cancer Res"},{"key":"CITATION32","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41401-020-0443-1","volume":"42","author":"Ma CS","year":"2021","unstructured":"Ma CS, Lv QM, Zhang KR, Tang YB, Zhang YF, Shen Y, Lei HM. NRF2-GPX4\/SOD2 axis imparts resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer cells. Acta Pharmacol Sin, 2021, 42: 613-623.","journal-title":"Acta Pharmacol Sin"},{"key":"CITATION33","doi-asserted-by":"publisher","first-page":"445","DOI":"10.4143\/crt.2016.572","volume":"50","author":"Guo J","year":"2018","unstructured":"Guo J, Xu B, Han Q, Zhou H, Xia Y, Gong C, Dai X. Ferroptosis: a novel anti-tumor action for cisplatin. Cancer Res Treat, 2018, 50: 445-460.","journal-title":"Cancer Res Treat"},{"key":"CITATION34","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.canlet.2016.07.035","volume":"381","author":"Roh JL","year":"2016","unstructured":"Roh JL, Kim EH, Jang HJ, Park JY, Shin D. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer. Cancer Lett, 2016, 381: 96-103.","journal-title":"Cancer Lett"},{"key":"CITATION35","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41568-020-00308-y","volume":"21","author":"Rottenberg S","year":"2021","unstructured":"Rottenberg S, Disler C, Perego P. The rediscovery of platinum-based cancer therapy. Nat Rev Cancer, 2021, 21: 37-50.","journal-title":"Nat Rev Cancer"},{"key":"CITATION36","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.molcel.2016.02.009","volume":"61","author":"Li X","year":"2016","unstructured":"Li X, Jiang Y, Meisenhelder J, Yang W, Hawke DH, Zheng Y, Xia Y. Mitochondria-translocated PGK1 functions as a protein kinase to coordinate glycolysis and the TCA cycle in tumorigenesis. Mol Cell, 2016, 61: 705-719.","journal-title":"Mol Cell"},{"key":"CITATION37","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/s41419-018-0844-y","volume":"9","author":"Chen Y","year":"2018","unstructured":"Chen Y, Wu YR, Yang HY, Li XZ, Jie MM, Hu CJ, Wu YY. Prolyl isomerase PIN1: a promoter of cancer and a target for therapy. Cell Death Dis, 2018, 9:","journal-title":"Cell Death Dis"},{"key":"CITATION38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccell.2018.03.022","volume":"34","author":"Rojo de la Vega M","year":"2018","unstructured":"Rojo de la Vega M, Chapman E, Zhang DD. NRF2 and the hallmarks of cancer. Cancer Cell, 2018, 34: 21-43.","journal-title":"Cancer Cell"},{"key":"CITATION39","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3389\/fnins.2018.00466","volume":"12","author":"Abdalkader M","year":"2018","unstructured":"Abdalkader M, Lampinen R, Kanninen KM, Malm TM, Liddell JR. Targeting NRF2 to suppress ferroptosis and mitochondrial dysfunction in neurodegeneration. Front Neurosci, 2018, 12:","journal-title":"Front Neurosci"},{"key":"CITATION40","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature24297","volume":"551","author":"Hangauer MJ","year":"2017","unstructured":"Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, Galeas J. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature, 2017, 551: 247-250.","journal-title":"Nature"},{"key":"CITATION41","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/cbin.11121","volume":"43","author":"Liu Q","year":"2019","unstructured":"Liu Q, Wang K. The induction of ferroptosis by impairing STAT3\/NRF2\/GPx4 signaling enhances the sensitivity of osteosarcoma cells to cisplatin. Cell Biol Int, 2019, 43: 1245-1256.","journal-title":"Cell Biol Int"},{"key":"CITATION42","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1093\/abbs\/gmaa129","volume":"52","author":"Sun T","year":"2020","unstructured":"Sun T, Zhang J, Deng B, Fan X, Long T, Jin H, Tao S. FOXO1 and FOXO3a sensitize non-small-cell lung cancer cells to cisplatin-induced apoptosis independent of Bim. Acta Biochim Biophys Sin, 2020, 52: 1348-1359.","journal-title":"Acta Biochim Biophys Sin"},{"key":"CITATION43","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1093\/abbs\/gmaa097","volume":"52","author":"Li Q","year":"2020","unstructured":"Li Q, Wang M, Zhang Y, Wang L, Yu W, Bao X, Zhang B. BIX-01294-enhanced chemosensitivity in nasopharyngeal carcinoma depends on autophagy-induced pyroptosis. Acta Biochim Biophys Sin, 2020, 52: 1131-1139.","journal-title":"Acta Biochim Biophys Sin"},{"key":"CITATION44","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1093\/abbs\/gmab080","volume":"53","author":"Hou Y","year":"2021","unstructured":"Hou Y, Fan Y, Xia X, Pan J, Hou J, Liu X, Chen X. USP31 acetylation at Lys1264 is essential for its activity and cervical cancer cell growth. Acta Biochim Biophys Sin, 2021, 53: 1037-1043.","journal-title":"Acta Biochim Biophys Sin"},{"key":"CITATION45","doi-asserted-by":"publisher","first-page":"e22068","DOI":"10.1096\/fj.202100776RR","volume":"36","author":"Saeidi S","year":"2022","unstructured":"Saeidi S, Kim SJ, Guillen-Quispe YN, Jagadeesh ASV, Han HJ, Kim SH, Zhong X. Peptidyl\u2010prolyl cis\u2010trans isomerase NIMA\u2010interacting 1 directly binds and stabilizes Nrf2 in breast cancer. FASEB J, 2022, 36:","journal-title":"FASEB J"},{"key":"CITATION46","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/j.freeradbiomed.2010.03.013","volume":"48","author":"Kim SE","year":"2010","unstructured":"Kim SE, Lee MY, Lim SC, Hien TT, Kim JW, Ahn SG, Yoon JH. Role of Pin1 in neointima formation: down-regulation of Nrf2-dependent heme oxygenase-1 expression by Pin1. Free Radical Biol Med, 2010, 48: 1644-1653.","journal-title":"Free Radical Biol Med"}],"container-title":["Acta Biochimica et Biophysica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/engine.scichina.com\/doi\/pdf\/7423FAA42C814855A1DE8ECAF4DF6C51","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/engine.scichina.com\/doi\/10.3724\/abbs.2022109","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/engine.scichina.com\/doi\/pdf\/7423FAA42C814855A1DE8ECAF4DF6C51","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T21:22:17Z","timestamp":1660771337000},"score":1,"resource":{"primary":{"URL":"https:\/\/engine.scichina.com\/doi\/10.3724\/abbs.2022109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":46,"URL":"https:\/\/doi.org\/10.3724\/abbs.2022109","relation":{},"ISSN":["1672-9145"],"issn-type":[{"value":"1672-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,1]]}}}